187 related articles for article (PubMed ID: 37964212)
21. Reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to assess Chemotherapy-induced peripheral neuropathy.
Kim HY; Kang JH; Youn HJ; So HS; Song CE; Chae SY; Jung SH; Kim SR; Kim JY
J Korean Acad Nurs; 2014 Dec; 44(6):735-42. PubMed ID: 25608551
[TBL] [Abstract][Full Text] [Related]
22. Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.
Balayssac D; Kerckhove N; Selvy M; Pereira B; Gonneau C; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Pezet D; Martin V
Support Care Cancer; 2024 Jun; 32(7):427. PubMed ID: 38869647
[TBL] [Abstract][Full Text] [Related]
23. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.
Alberti P; Rossi E; Cornblath DR; Merkies IS; Postma TJ; Frigeni B; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Faber CG; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Valsecchi MG; Cavaletti G;
Ann Oncol; 2014 Jan; 25(1):257-64. PubMed ID: 24256846
[TBL] [Abstract][Full Text] [Related]
24. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).
Kieffer JM; Postma TJ; van de Poll-Franse L; Mols F; Heimans JJ; Cavaletti G; Aaronson NK;
Qual Life Res; 2017 Nov; 26(11):2999-3010. PubMed ID: 28634676
[TBL] [Abstract][Full Text] [Related]
26. The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure.
Lavoie Smith EM; Haupt R; Kelly JP; Lee D; Kanzawa-Lee G; Knoerl R; Bridges C; Alberti P; Prasertsri N; Donohoe C
Oncol Nurs Forum; 2017 Sep; 44(5):580-588. PubMed ID: 28820525
[TBL] [Abstract][Full Text] [Related]
27. Assessment of chemotherapy-induced neurotoxicity using a point-of-care nerve conduction study device.
Jokimäki A; Iivanainen S; Mikkonen R; Mika K; Koivunen J
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1677. PubMed ID: 35818348
[TBL] [Abstract][Full Text] [Related]
28. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
Oh PJ; Lee JR; Kim SK; Kim JH
Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
[TBL] [Abstract][Full Text] [Related]
29. A new monitoring tool CLIP test for progression of oxaliplatin-induced peripheral neuropathy: A multicenter prospective study.
Kamei K; Ohnishi T; Nakata K; Danno K; Ohkawa A; Miyake Y; Okazaki S; Fukunaga M; Toyokawa A; Hamada T; Shindoh J; Kanazawa A
Asia Pac J Clin Oncol; 2020 Oct; 16(5):e257-e262. PubMed ID: 32893979
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study.
Chen CS; Kim J; Garg N; Guntupalli H; Jagsi R; Griggs JJ; Sabel M; Dorsch MP; Callaghan BC; Hertz DL
JMIR Mhealth Uhealth; 2021 Jul; 9(7):e27502. PubMed ID: 36260403
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
[TBL] [Abstract][Full Text] [Related]
32. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
33. IMPACT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY ON THE QUALITY OF LIFE IN CANCER PATIENTS.
Novak M; Miličević J; Bišof V
Acta Clin Croat; 2022 Mar; 61(1):52-61. PubMed ID: 36530966
[TBL] [Abstract][Full Text] [Related]
34. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.
Postma TJ; Aaronson NK; Heimans JJ; Muller MJ; Hildebrand JG; Delattre JY; Hoang-Xuan K; Lantéri-Minet M; Grant R; Huddart R; Moynihan C; Maher J; Lucey R;
Eur J Cancer; 2005 May; 41(8):1135-9. PubMed ID: 15911236
[TBL] [Abstract][Full Text] [Related]
35. Study on efficacy and safety of Huangqi Guizhi Wuwu decoction treatment for oxaliplatin induced peripheral neurotoxicity: A protocol for a randomized, controlled, double-blind, multicenter trial.
Wei XM; Chen XF; Shu P; Jiang ZW; Wu XY; Zou X; Chen K; Shen B; Hu WW; Lu W; Shen WX; Li L; Wang JY; Zhao FJ; Yin QF; Cheng HB; Gu YH
Medicine (Baltimore); 2020 May; 99(22):e19923. PubMed ID: 32481364
[TBL] [Abstract][Full Text] [Related]
36. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool.
Tofthagen CS; McMillan SC; Kip KE
Cancer Nurs; 2011; 34(4):E10-20. PubMed ID: 21242773
[TBL] [Abstract][Full Text] [Related]
37. Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
Miura Y; Ando M; Yamazaki K; Hironaka S; Boku N; Muro K; Hyodo I
Support Care Cancer; 2021 Jul; 29(7):3715-3723. PubMed ID: 33200233
[TBL] [Abstract][Full Text] [Related]
38. Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy.
McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Friedlander M; Bosco A; Harrison M; Maier N; O'Neill S; Park SB
J Pain Symptom Manage; 2019 Dec; 58(6):1023-1032. PubMed ID: 31374367
[TBL] [Abstract][Full Text] [Related]
39. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial.
Lemanska A; Harkin A; Iveson T; Kelly C; Saunders M; Faithfull S
ESMO Open; 2023 Dec; 8(6):102063. PubMed ID: 37988949
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors.
Orszaghova Z; Galikova D; Lesko P; Obertova J; Rejlekova K; Sycova-Mila Z; Palacka P; Kalavska K; Svetlovska D; Mladosievicova B; Mardiak J; Mego M; Chovanec M
Clin Genitourin Cancer; 2024 Jun; 22(3):102067. PubMed ID: 38555680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
